Chlorpromazine
Based on 129 publication(s) in Google Scholar
Chlorpromazine is an orally active, blood-brain barrier-transparent antipsychotic agent that effectively antagonises D2 dopamine receptors and 5-HT2A, which is widely used in schizophrenia and other psychiatric disorders. Chlorpromazine exerts anti-cancer activity through a variety of pathways, including anti-proliferation, induction of autophagy and cycle arrest (G2-M phase), inhibition of cytochrome c oxidase (CcO), inhibition of tumour growth and metastasis, and inhibition of tumour immune escape. Chlorpromazine also blocks hNav1.7 channels (IC50=25.9 μM; concentration-dependent) and HERG potassium channels (IC50=21.6 μM), which has potential for analgesic and cardiac arrhythmic studies. Chlorpromazine also can inhibit clathrin-mediated endocytosis.
For research use only. We do not sell to patients.
- Purity: 99.75%
- CAS No.: 50-53-3
- Formula: C17H19ClN2S
- Molecular Weight:318.86
-
Storage:
4°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
Publications Citing Use of MedChemExpress (MCE) Chlorpromazine
More- Signal Transduct Target Ther. 2025 Oct 21;10(1):349. [Abstract]
- Nat Nanotechnol. 2024 Dec;19(12):1903-1913. [Abstract]
- Cell Metab. 2024 Jun 18:S1550-4131(24)00189-X. [Abstract]
- Cell Metab. 2022 Dec 6;34(12):2018-2035.e8. [Abstract]
- Adv Mater. 2025 Jan 10:e2415030. [Abstract]
- Nat Biomed Eng. 2024 Nov;8(11):1469-1482. [Abstract]
- Adv Funct Mater. 2024 Oct 31.
- Adv Funct Mater. 2023 Jan 15.
- Adv Funct Mater. 2020, 2004940.
- Cancer Res. 2025 Oct 9. [Abstract]
- ACS Nano. 2026 Feb 17;20(6):5157-5170. [Abstract]
- ACS Nano. 2025 Dec 26. [Abstract]
- ACS Nano. 2023 May 9;17(9):8141-8152. [Abstract]
- ACS Nano. 2020 Nov 24;14(11):14698-14714. [Abstract]
- Nat Commun. 2025 Dec 12;16(1):11314. [Abstract]
- Nat Commun. 2025 Sep 26;16(1):8522. [Abstract]
- Nat Commun. 2025 Aug 27;16(1):7994. [Abstract]
- Nat Commun. 2025 Mar 10;16(1):2368. [Abstract]
- J Am Chem Soc. 2018 Dec 12;140(49):17234-17240. [Abstract]
- BMEmat. 2026 Feb 11.
- Acta Pharm Sin B. 2025 Oct;15(10):5431-5443. [Abstract]
- Acta Pharm Sin B. 2024 Oct;14(10):4509-4525. [Abstract]
- J Extracell Vesicles. 2026 Feb;15(2):e70238. [Abstract]
- J Extracell Vesicles. 2024 Dec;13(12):e70025. [Abstract]
- Adv Sci (Weinh). 2025 Dec 23:e17792. [Abstract]
- Adv Sci (Weinh). 2025 Sep 3:e02788. [Abstract]
- Adv Sci (Weinh). 2025 May 14:e2406150. [Abstract]
- Adv Sci (Weinh). 2025 Apr 3:e2412356. [Abstract]
- Adv Sci (Weinh). 2023 Jun;10(17):e2207017. [Abstract]
- Nat Plants. 2025 Sep 12. [Abstract]
- Theranostics. 2021 May 24;11(15):7308-7321. [Abstract]
- Theranostics. 2020 May 17;10(15):6581-6598. [Abstract]
- Theranostics. 2019 May 31;9(13):3732-3753. [Abstract]
- Chem Eng J. 2025 Jul 1.
- Chem Eng J. 2024 Sep 1.
- Chem Eng J. 2024 Apr 15, 486 150125.
- Biomaterials. 2026 Jan:324:123541. [Abstract]
- Biomaterials. 2022 Feb:281:121373. [Abstract]
- J Nanobiotechnology. 2025 Aug 6;23(1):554. [Abstract]
- Carbohydr Polym. 2025 Nov 15;368(Pt 1):124067. [Abstract]
- Small. 2026 Mar;22(18):e13435. [Abstract]
- J Control Release. 2026 May 10:393:114784. [Abstract]
- J Control Release. 2025 Dec 16:390:114551. [Abstract]
- J Control Release. 2025 Nov 30:389:114488. [Abstract]
- J Control Release. 2025 Nov 20:389:114450. [Abstract]
- J Control Release. 2025 Aug 29:387:114176. [Abstract]
- J Control Release. 2025 Jan 8:379:45-58. [Abstract]
- J Control Release. 2024 Oct 26:S0168-3659(24)00725-9. [Abstract]
- J Control Release. 2024 Jun:370:140-151. [Abstract]
- J Hazard Mater. 2025 Dec 5:500:140498. [Abstract]
- Environ Sci Technol. 2021 Mar 2;55(5):3144-3155. [Abstract]
- J Immunother Cancer. 2023 Jan;11(1):e005592. [Abstract]
- Mater Today Bio. 2025 Nov 13:35:102547. [Abstract]
- Mater Today Bio. 2025 Jul 10:33:102074. [Abstract]
- Mater Today Bio. 2025 Mar 27:32:101712. [Abstract]
- Mater Today Bio. 2025 Apr 17:32:101778. [Abstract]
- J Colloid Interface Sci. 2025 Jun 18;699(Pt 2):138235. [Abstract]
- Adv Healthc Mater. 2025 May 24:e2500507. [Abstract]
- Acta Biomater. 2025 Jul 1:201:171-186. [Abstract]
- Acta Biomater. 2025 Jan 24:193:498-513. [Abstract]
- Sci China Life Sci. 2025 Oct 24. [Abstract]
- Sci China Life Sci. 2024 Dec;67(12):2713-2729. [Abstract]
- Sci China Life Sci. 2022 Feb;65(2):341-361. [Abstract]
- J Pharm Anal. 2025 Jul;15(7):101182. [Abstract]
- Cell Commun Signal. 2023 May 4;21(1):99. [Abstract]
- Cell Commun Signal. 2020 Nov 4;18(1):176. [Abstract]
- Cell Commun Signal. 2019 May 23;17(1):49 [Abstract]
- Int J Biol Macromol. 2026 Jan 7;340:150099.
- Int J Biol Macromol. 2025 Apr 28;310(Pt 4):143599. [Abstract]
- Int J Biol Macromol. 2022 May 15:207:559-569. [Abstract]
- ACS Appl Mater Interfaces. 2025 Apr 17. [Abstract]
- Drug Deliv. 2025 Dec;32(1):2509962. [Abstract]
- Food Res Int. 2025 Dec 20;226:118114.
- Sci Total Environ. 2021 Jul 20:779:146523. [Abstract]
- Br J Pharmacol. 2025 Nov 14. [Abstract]
- Br J Pharmacol. 2023 Jul;180(14):1878-1896. [Abstract]
- Br J Pharmacol. 2020 Aug;177(15):3473-3488. [Abstract]
- Emerg Microbes Infect. 2022 Dec;11(1):483-497. [Abstract]
- Chem Mater. 2025 Jan 18.
- Microbiol Res. 2023 Aug:273:127421. [Abstract]
- J Med Chem. 2026 Apr 9;69(7):8417-8432. [Abstract]
- J Med Chem. 2023 Dec 28;66(24):16579-16596. [Abstract]
- Anal Chem. 2020 Sep 1;92(17):11921-11926. [Abstract]
- Int J Nanomedicine. 2025 Dec 6:20:14613-14628. [Abstract]
- Int J Nanomedicine. 2025 May 22:20:6573-6590. [Abstract]
- Int J Nanomedicine. 2025 Mar 27:20:3845-3860. [Abstract]
- Phytother Res. 2023 Aug;37(8):3296-3308. [Abstract]
- Front Immunol. 2021 Aug 2;12:686846. [Abstract]
- Colloids Surf B Biointerfaces. 2026 Jun:262:115536. [Abstract]
- Colloids Surf B Biointerfaces. 2025 Jun 3:254:114847. [Abstract]
- ACS Appl Nano Mater. 2025 Mar 19.
- Pharmaceutics. 2024 Nov 21;16(12):1496. [Abstract]
- Drug Deliv Transl Res. 2024 Mar;14(3):621-636. [Abstract]
- Arab J Chem. 2020, 13 (1): 2558-2567.
- Commun Biol. 2022 Nov 14;5(1):1248. [Abstract]
- Int J Mol Sci. 2025 Mar 29;26(7):3172. [Abstract]
- Pharm Biol. 2022 Dec;60(1):1679-1689. [Abstract]
- ACS Appl Polym Mater. 2026 Feb 25.
- mBio. 2026 Apr 8;17(4):e0389625. [Abstract]
- mBio. 2025 Mar 12;16(3):e0378724. [Abstract]
- Biol Res. 2023 Mar 11;56(1):10. [Abstract]
- Front Cell Dev Biol. 2023 Sep 8:11:1266198. [Abstract]
- Front Cell Dev Biol. 2021 Jul 7;9:687322. [Abstract]
- Front Cell Dev Biol. 2021 Mar 18:9:640667. [Abstract]
- Comput Struct Biotechnol J. 2021;19:1933-1943. [Abstract]
- Toxins. 2021 Mar 2;13(3):184. [Abstract]
- Antiviral Res. 2020 Jun;178:104786. [Abstract]
- Langmuir. 2020 Sep 29;36(38):11374-11382. [Abstract]
- J Virol. 2026 Mar 24;100(3):e0195225. [Abstract]
- J Virol. 2021 Nov 23;95(24):e0134521. [Abstract]
- Microb Pathog. 2025 May 26:206:107751. [Abstract]
- Viruses. 2021 May 31;13(6):1035. [Abstract]
- PLoS Negl Trop Dis. 2019 Aug 20;13(8):e0007681. [Abstract]
- J Leukoc Biol. 2024 Jul 16:qiae159. [Abstract]
- Insect Sci. 2020 Aug;27(4):675-686. [Abstract]
- Virus Res. 2024 Oct 19:350:199485. [Abstract]
- Virus Res. 2020 Jan 15;276:197806. [Abstract]
- Biochim Biophys Acta Gen Subj. 2023 Mar;1867(3):130300. [Abstract]
- bioRxiv. 2026 Apr 3.
- Cell Biomater. 2026 Mar 6.
- Res Sq. 2026 Feb 5.
- SSRN. 2025 Sep 30.
- University of Toronto. 2025.
- Journal of Dermatologic Science and Cosmetic Technology. 2025 Jun.
- bioRxiv. 2025 May 06.
- SSRN. 2025 Mar 25.
- Extracell Vesicle. 2025 Jun.
- Research Square Preprint. 2024 Apr 22.
- Research Square Print. 2023 Mar 20.
-
Flow Cytometry
-
Flow Cytometry
-
Flow Cytometry
-
Flow Cytometry
-
IF
All Dopamine Receptor Isoforms
MoreAll 5-HT Receptor Isoforms
More
Biological Activity
|
5-HT2A Receptor |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO | IC50 |
3.4 μM
Compound: chlorpromazine
|
Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits
Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits
|
[PMID: 23812503] |
| CHO-K1 | IC50 |
1 nM
Compound: Chlorpromazine
|
Antagonist activity against human recombinant dopmaine D2L receptor expressed in CHOK1 cells assessed as reduction in apomorphine-induced increase in intracellular Ca2+ levels by aequorin based radiometric and luminescence plate counting method
Antagonist activity against human recombinant dopmaine D2L receptor expressed in CHOK1 cells assessed as reduction in apomorphine-induced increase in intracellular Ca2+ levels by aequorin based radiometric and luminescence plate counting method
|
[PMID: 25557493] |
| CHO-K1 | IC50 |
1 nM
Compound: Chlorpromazine
|
Antagonist activity at human dopamine D2 receptor expressed in CHOK1 cells assessed as inhibition of apomorphine-induced calcium mobilization by radiometric and luminescence plate counting method
Antagonist activity at human dopamine D2 receptor expressed in CHOK1 cells assessed as inhibition of apomorphine-induced calcium mobilization by radiometric and luminescence plate counting method
|
[PMID: 25557493] |
| Cortical neurone | IC50 |
13.8 μM
Compound: Chlorpromazine
|
Neurotoxicity in rat cortical neuron assessed as inhibition of neurite total length per neuron incubated for 72 hrs by Hoechst 33342 staining based ArrayScan analysis
Neurotoxicity in rat cortical neuron assessed as inhibition of neurite total length per neuron incubated for 72 hrs by Hoechst 33342 staining based ArrayScan analysis
|
[PMID: 31841637] |
| Cortical neurone | IC50 |
7.99 μM
Compound: Chlorpromazine
|
Neurotoxicity in rat cortical neuron assessed as inhibition of valid neuron count incubated for 72 hrs by Hoechst 33342 staining based ArrayScan analysis
Neurotoxicity in rat cortical neuron assessed as inhibition of valid neuron count incubated for 72 hrs by Hoechst 33342 staining based ArrayScan analysis
|
[PMID: 31841637] |
| Cortical neurone | IC50 |
9.022 μM
Compound: Chlorpromazine
|
Neurotoxicity in rat cortical neuron assessed as inhibition of neurite outgrowth by measuring mean neurite average length incubated for 72 hrs by Hoechst 33342 staining based ArrayScan analysis
Neurotoxicity in rat cortical neuron assessed as inhibition of neurite outgrowth by measuring mean neurite average length incubated for 72 hrs by Hoechst 33342 staining based ArrayScan analysis
|
[PMID: 31841637] |
| HaCaT | IC50 |
36.1 μM
Compound: CPZ
|
Phototoxicity in human HaCaT cells assessed as reduction in cell viability preincubated for 60 mins followed by 7.5 J/cm2 UVA irradiation and measured after 24 hrs by neutral red uptake assay
Phototoxicity in human HaCaT cells assessed as reduction in cell viability preincubated for 60 mins followed by 7.5 J/cm2 UVA irradiation and measured after 24 hrs by neutral red uptake assay
|
[PMID: 29604584] |
| HEK293 | IC50 |
27 μM
Compound: chlorpromazine
|
Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells by confocal microscopy
Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells by confocal microscopy
|
[PMID: 18788725] |
| HeLa | IC50 |
4.3 μM
Compound: Chlorpromazine
|
TP_TRANSPORTER: inhibition of TEA uptake in OCT1-expressing HeLa cells
TP_TRANSPORTER: inhibition of TEA uptake in OCT1-expressing HeLa cells
|
[PMID: 12606755] |
| Macrophage cell line | CC50 |
22.24 μM
Compound: CPZ
|
Cytotoxicity in human monocyte-derived macrophages assessed as reduction in cell viability incubated for 3 days by alamar blue dye based assay
Cytotoxicity in human monocyte-derived macrophages assessed as reduction in cell viability incubated for 3 days by alamar blue dye based assay
|
[PMID: 28964936] |
| NCI-H1650 | GI50 |
30.3 μM
Compound: Chlorpromazine
|
Cytotoxicity against human NCI-H1650 cells assessed as growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human NCI-H1650 cells assessed as growth inhibition after 48 hrs by MTT assay
|
[PMID: 26372073] |
| NHDF | IC50 |
25.5 μM
Compound: CPZ
|
Phototoxicity in human NHDF cells assessed as reduction in cell viability preincubated for 60 mins followed by 5 J/cm2 UVA irradiation and measured after 24 hrs by neutral red uptake assay
Phototoxicity in human NHDF cells assessed as reduction in cell viability preincubated for 60 mins followed by 5 J/cm2 UVA irradiation and measured after 24 hrs by neutral red uptake assay
|
[PMID: 29604584] |
| NIH3T3 | IC50 |
0.93 μg/mL
Compound: Chlorpromazine
|
Phototoxicity against BALB/c mouse 3T3 cells assessed as reduction in cell viability preincubated for 1 hr followed by 5 J/cm2 irradiation and subsequent replacement of medium without compound and measured after 24 hrs by neutral red dye based assay
Phototoxicity against BALB/c mouse 3T3 cells assessed as reduction in cell viability preincubated for 1 hr followed by 5 J/cm2 irradiation and subsequent replacement of medium without compound and measured after 24 hrs by neutral red dye based assay
|
[PMID: 38128906] |
| NIH3T3 | IC50 |
45.08 μg/mL
Compound: Chlorpromazine
|
Dark toxicity against BALB/c mouse 3T3 cells assessed as reduction in cell viability incubated for 1 hr by neutral red dye based assay
Dark toxicity against BALB/c mouse 3T3 cells assessed as reduction in cell viability incubated for 1 hr by neutral red dye based assay
|
[PMID: 38128906] |
| ScN2a | EC50 |
2 μM
Compound: Chlorpromazine
|
Half maximal inhibition of Prion protein PrPsc formation was assayed in ScN2a cells
Half maximal inhibition of Prion protein PrPsc formation was assayed in ScN2a cells
|
[PMID: 12904059] |
| Sf21 | IC50 |
122.3 μM
Compound: Chlorpromazine
|
Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake
Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake
|
[PMID: 21965623] |
| Sf21 | IC50 |
147.6 μM
Compound: Chlorpromazine
|
Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake
Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake
|
[PMID: 21965623] |
| Vero | IC50 |
26.52 μg/mL
Compound: CPZ
|
Cytotoxicity against African green monkey Vero cells assessed as decrease in cell viability incubated for 72 hrs by resazurin assay
Cytotoxicity against African green monkey Vero cells assessed as decrease in cell viability incubated for 72 hrs by resazurin assay
|
[PMID: 32526553] |
| WI-38 | CC50 |
10.34 μM
Compound: Chlorpromazine
|
Cytotoxicity against human WI38 cells assessed as reduction in cellular DNA level preincubated for 2 hrs before viral infection measured after 7 days by real time PCR assay
Cytotoxicity against human WI38 cells assessed as reduction in cellular DNA level preincubated for 2 hrs before viral infection measured after 7 days by real time PCR assay
|
[PMID: 17893158] |
| WI-38 | EC50 |
7.6 μM
Compound: Chlorpromazine
|
Antiviral activity against BKV Gardner ATCC VR837 infected in human WI38 cells assessed as reduction in viral DNA level preincubated for 2 hrs before viral infection measured after 7 days by real time PCR assay
Antiviral activity against BKV Gardner ATCC VR837 infected in human WI38 cells assessed as reduction in viral DNA level preincubated for 2 hrs before viral infection measured after 7 days by real time PCR assay
|
[PMID: 17893158] |
Chlorpromazine (0, 10, 20, 40 μM; 0, 24, 48 h) inhibits growth of U-87MG glioma cells in a dose- and time- dependent manner[2].
Chlorpromazine (20 μM; 0, 12, 24, 48 h) decreases the levels of cyclin A and cyclin B1 in U-87MG glioma cells, 12 h later[2].
Chlorpromazine (20 μM) causes inhibition of cell cycle progression[2].
Chlorpromazine (10 μM; 1 h) significantly suppresses the sEV internalization and dramatically reduces MDSCs in sEV-treated bone marrow cells (MDSCs can significantly suppress the immune cell response, causing immunosuppression in cancer cells)[3].
Chlorpromazine (3, 10, 20, 40, 60 μM) blocks the hNav1.7 current in a concentration-dependent manner[4].
Chlorpromazine blocks HERG potassium channels with an IC50 value of 21.6 μM and a Hill coefficient of 1.11[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:U-87MG glioma cells
-
Concentration:0, 10, 20, 40 μM
-
Incubation Time:0, 24, 48 h
-
Result:Showed anti-proliferative activity in a dose- and time-dependent manner.
-
Cell Line:Bone marrow cells (sEV-treated)
-
Concentration:10 µM
-
Incubation Time:1 h
-
Result:Reduced MDSCs and suppressed the sEV internalization.
-
Cell Line:U-87MG glioma cells
-
Concentration:20 μM
-
Incubation Time:0, 12, 24, 48 h
-
Result:Decreased the levels of cyclin A and cyclin B1 12 h later, whereas levels of cyclin D1, proliferating cell nuclear antigen and GAPDH remained unchanged.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:5- to 6-week-old athymic nude mice bearing intracranial U-87MG xenograft tumors[2].
-
Dosage:20 mg/kg
-
Administration:Injected intraperitoneally; single daily for 7 days
-
Result:Inhibited tumor growth on day 17.
Chemical Information
-
CAS No. 50-53-3
-
Appearance Solid
-
Molecular Weight 318.86
-
Formula C17H19ClN2S
-
Color White to off-white
-
SMILES
CN(C)CCCN1C2=C(C=CC=C2)SC3=CC=C(Cl)C=C13
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
Publications (129)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
Condensate nanovaccine adjuvants augment CD8+ T-Cell-dependent antitumor immunity through mtDNA leakage-triggered cGAS-STING axis activation. [Abstract]2025 Oct 21;10(1):349. PMID: 41115902
Chlorpromazine purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2025 Oct 21;10(1):349. [Abstract]
Analysis of the cellular uptake pathways of OVA PCD. Ethamilamiline (EIPA), genistein (GEN), and chlorpromazine (CPZ) (10 μM for 12 h)were used to inhibit macropinocytosis, caveolin-mediated endocytosis, and clathrin-mediated endocytosis, respectively.
-
Nat Nanotechnol
Metal-ion-chelating phenylalanine nanostructures reverse immune dysfunction and sensitize breast tumour to immune checkpoint blockade. [Abstract]2024 Dec;19(12):1903-1913. PMID: 39187583 -
Cell Metab
Nicotinamide metabolism face-off between macrophages and fibroblasts manipulates the microenvironment in gastric cancer. [Abstract]2024 Jun 18:S1550-4131(24)00189-X. PMID: 38897198
Chlorpromazine purchased from MedChemExpress. Usage Cited in: Cell Metab. 2024 Jun 18:S1550-4131(24)00189-X. [Abstract]
To clarify the possible pathways responsible for EV uptake by CAFs, BMDM-derived EVs were labeled with DiO, and m-CAFs were labeled with DiL. Chlorpromazine (50 μM, 1h) was used to block EV uptake by m-CAFs.
-
Cell Metab
Cancer cell-intrinsic XBP1 drives immunosuppressive reprogramming of intratumoral myeloid cells by promoting cholesterol production. [Abstract]2022 Dec 6;34(12):2018-2035.e8. PMID: 36351432
Chlorpromazine purchased from MedChemExpress. Usage Cited in: Cell Metab. 2022 Dec 6;34(12):2018-2035.e8. [Abstract]
Bone marrow cells cultured in medium containing 10 ng/mL GM-CSF for 3 days were treated with 2 μg PKH67-labeled sEVs with or without Amiloride (10 μM), Chlorpromazine (10 μM), or EIPA (5 μM) for 1 h. The median fluorescence intensity (MFI) of PKH67 was assessed by flow cytometry.
-
Adv Mater
Self-Sustained Biophotocatalytic Nano-Organelle Reactors with Programmable DNA Switches for Combating Tumor Metastasis. [Abstract]2025 Jan 10:e2415030. PMID: 39797479
Chlorpromazine purchased from MedChemExpress. Usage Cited in: Adv Mater. 2025 Jan 10:e2415030. [Abstract]
FCM analysis of F/G/H‐GNC internalization by 4T1 cells pre‐treated with various endocytosis inhibitors (n = 3). EIPA: 5‐(N‐ethyl‐N‐isopropyl)‐amiloride, 50 µM; Dyna: dynasore, 50 µg/mL; Me‐β‐CD: methyl‐β‐cyclodextrin, 2.5 mg/mL; CPZ: Chlorpromazine, 10 µg/mL; Cyto D: Cytochalasin D, 2.5 µg/mL; Noco: Nocodazole, 5 µM.
-
Nat Biomed Eng
In situ formation of biomolecular condensates as intracellular drug reservoirs for augmenting chemotherapy. [Abstract]2024 Nov;8(11):1469-1482. PMID: 39271933 -
-
-
-
Cancer Res
Targeting Sialylation Enhances the Therapeutic Efficacy of the Nectin-4-Targeted Antibody-Drug Conjugate Enfortumab Vedotin in Bladder Cancer. [Abstract]2025 Oct 9. PMID: 41066596 -
ACS Nano
2026 Feb 17;20(6):5157-5170. PMID: 41620948 -
ACS Nano
Redox-Responsive Peptide Coacervates for Enhanced mRNA Delivery and Intracellular Release. [Abstract]2025 Dec 26. PMID: 41451635 -
ACS Nano
Enantioselective Degrader for Elimination of Extracellular Aggregation-Prone Proteins hIAPP Associated with Type 2 Diabetes. [Abstract]2023 May 9;17(9):8141-8152. PMID: 37057955 -
ACS Nano
Modular Peptide Probe for Pre/Intra/Postoperative Therapeutic to Reduce Recurrence in Ovarian Cancer. [Abstract]2020 Nov 24;14(11):14698-14714. PMID: 33174739 -
Nat Commun
Transferrin-phosphatidylserine liposomes target TDP-43 and neuroinflammation in male mice with neuropathic pain. [Abstract]2025 Dec 12;16(1):11314. PMID: 41387431 -
Nat Commun
Ocular delivery of lipid nanoparticles-formulated mRNA encoding lanosterol synthase ameliorates cataract in rats. [Abstract]2025 Sep 26;16(1):8522. PMID: 41006301 -
Nat Commun
Microglial replacement in a Sandhoff disease mouse model reveals myeloid-derived β-hexosaminidase is necessary for neuronal health. [Abstract]2025 Aug 27;16(1):7994. PMID: 40866328 -
Nat Commun
Berberine-inspired ionizable lipid for self-structure stabilization and brain targeting delivery of nucleic acid therapeutics. [Abstract]2025 Mar 10;16(1):2368. PMID: 40064874 -
J Am Chem Soc
2018 Dec 12;140(49):17234-17240. PMID: 30398334 -
-
Acta Pharm Sin B
Spatiotemporally delivery of Cas9 ribonucleoprotein/DNAzyme logic systems using near-infrared upconversion nanomachine for precise immunotherapy. [Abstract]2025 Oct;15(10):5431-5443. PMID: 41132842 -
Acta Pharm Sin B
Cocrystal@protein-anchoring nanococktail for combinatorially treating multidrug-resistant cancer. [Abstract]2024 Oct;14(10):4509-4525. PMID: 39525582 -
J Extracell Vesicles
Extracellular Vesicles Coordinate Bacterial Cloaking in Lung Epithelial Cells to Alleviate Acute Inflammatory Injury. [Abstract]2026 Feb;15(2):e70238. PMID: 41656978 -
J Extracell Vesicles
CD7-targeting pro-apoptotic extracellular vesicles: A novel approach for T-cell haematological malignancy therapy. [Abstract]2024 Dec;13(12):e70025. PMID: 39676736 -
Adv Sci (Weinh)
Biomimetic Nanomedicine for Senescence-Modulated Immune Activation Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma. [Abstract]2025 Dec 23:e17792. PMID: 41432006 -
Adv Sci (Weinh)
Physiological pH Transition-Driven Protein Corona Dynamics Regulate Cellular Uptake and Inflammatory Responses of Silica Nanoparticles. [Abstract]2025 Sep 3:e02788. PMID: 40902197 -
Adv Sci (Weinh)
Lipid Droplet-Derived Biomimetic Nanocarriers for the Enhancement of Porcine Intermuscular Fat Content. [Abstract]2025 May 14:e2406150. PMID: 40365640 -
Adv Sci (Weinh)
Screening and Identification of Novel DNA Aptamer for Targeted Delivery to Injured Podocytes in Glomerular Diseases. [Abstract]2025 Apr 3:e2412356. PMID: 40178289 -
Adv Sci (Weinh)
CCR7 Mediated Mimetic Dendritic Cell Vaccine Homing in Lymph Node for Head and Neck Squamous Cell Carcinoma Therapy. [Abstract]2023 Jun;10(17):e2207017. PMID: 37092579 -
Nat Plants
An apoplastic fungal effector disrupts N-glycosylation of ZmLecRK1, inducing its degradation to suppress disease resistance in maize. [Abstract]2025 Sep 12. PMID: 40940425 -
Theranostics
Adjuvant-free peptide vaccine targeting Clec9a on dendritic cells can induce robust antitumor immune response through Syk/IL-21 axis. [Abstract]2021 May 24;11(15):7308-7321. PMID: 34158852 -
Theranostics
Proinflammatory macrophage-derived microvesicles exhibit tumor tropism dependent on CCL2/CCR2 signaling axis and promote drug delivery via SNARE-mediated membrane fusion. [Abstract]2020 May 17;10(15):6581-6598. PMID: 32550891 -
Theranostics
A Multifunctional Nanotherapy for Targeted Treatment of Colon Cancer by Simultaneously Regulating Tumor Microenvironment. [Abstract]2019 May 31;9(13):3732-3753. PMID: 31281510 -
-
-
-
Biomaterials
Biodegradable polymers with tertiary amines enhance mRNA delivery of lipid nanoparticles via improved endosomal escape. [Abstract]2026 Jan:324:123541. PMID: 40644791 -
Biomaterials
Oral delivery of decanoic acid conjugated plant protein shell incorporating hybrid nanosystem leverage intestinal absorption of polyphenols. [Abstract]2022 Feb:281:121373. PMID: 35063742 -
J Nanobiotechnology
Intravesical delivery of mucoadhesive and tumor-selective-penetrating nanozymes for enhancing the PDT of bladder cancer. [Abstract]2025 Aug 6;23(1):554. PMID: 40770338 -
Carbohydr Polym
Premna microphylla Turcz pectin-modified diosmetin nanoparticles: A galectin-3 targeting strategy for precise colitis intervention. [Abstract]2025 Nov 15;368(Pt 1):124067. PMID: 40912828 -
Small
Dynamically Reprograms Mitochondrial Respiration to Augment Cuproptosis in Cancer Therapy. [Abstract]2026 Mar;22(18):e13435. PMID: 41653427 -
J Control Release
Intravitreal delivery of LATS1 mRNA by lipid nanoparticles as an effective strategy for uveal melanoma therapy. [Abstract]2026 May 10:393:114784. PMID: 41786044 -
J Control Release
Cyclization and thermal modulation of a β-hairpin peptide for efficient cellular delivery. [Abstract]2025 Dec 16:390:114551. PMID: 41412216 -
J Control Release
Bioswitchable intracellular delivery of small activating RNA by tetrahedral framework nucleic acid: Application to p21-mediated anti-tumor therapy. [Abstract]2025 Nov 30:389:114488. PMID: 41330514 -
J Control Release
Inducing potent ferroptosis in cancer cells by manipulation of ferritinophagy with a ferritin-targeted ATTEC. [Abstract]2025 Nov 20:389:114450. PMID: 41274571 -
J Control Release
Enzyme-instructed disassembly of phosphorylated temporin supramolecules enhances doxorubicin synergy for targeted cancer inhibition. [Abstract]2025 Aug 29:387:114176. PMID: 40886776 -
J Control Release
Combating cisplatin-resistant lung cancer using a coiled-coil lipopeptides modified membrane fused drug delivery system. [Abstract]2025 Jan 8:379:45-58. PMID: 39756686 -
J Control Release
2024 Oct 26:S0168-3659(24)00725-9. PMID: 39490420 -
J Control Release
A facile and smart strategy to enhance bone regeneration with efficient vitamin D3 delivery through sterosome technology. [Abstract]2024 Jun:370:140-151. PMID: 38653347 -
J Hazard Mater
CYP450 activation and mitophagy induction mediate Ti3C2 MXene detoxification in RAW 264.7 cells. [Abstract]2025 Dec 5:500:140498. PMID: 41252987 -
Environ Sci Technol
Graphene Quantum Dots Disrupt Embryonic Stem Cell Differentiation by Interfering with the Methylation Level of Sox 2. [Abstract]2021 Mar 2;55(5):3144-3155. PMID: 33569944 -
J Immunother Cancer
Tumor CEMIP drives immune evasion of colorectal cancer via MHC-I internalization and degradation. [Abstract]2023 Jan;11(1):e005592. PMID: 36596591 -
Mater Today Bio
SLC7A11-independent disulfidptosis induced by a two-pronged delivery strategy for bladder cancer chemotherapy and cisplatin-resistance reverse. [Abstract]2025 Nov 13:35:102547. PMID: 41322137 -
Mater Today Bio
Hyaluronic acid-anchored nanoparticles co-delivering emodin and siRNA confers protection against rheumatoid arthritis via macrophage polarization. [Abstract]2025 Jul 10:33:102074. PMID: 40688667 -
Mater Today Bio
Metal-organic framework-based delivery systems as nanovaccine for enhancing immunity against porcine circovirus type 2. [Abstract]2025 Mar 27:32:101712. PMID: 40230641 -
Mater Today Bio
Membrane biomimetic nanoenzyme-incorporated hybrid glycyrrhizic acid hydrogel for precise mitochondrial ROS scavenging for osteoarthritis treatment. [Abstract]2025 Apr 17:32:101778. PMID: 40290887 -
J Colloid Interface Sci
Porphyrin-based supramolecular chiral assembly for enantioselective interaction and augmented photodynamic therapy. [Abstract]2025 Jun 18;699(Pt 2):138235. PMID: 40544619 -
Adv Healthc Mater
Lipoprotein-Based Nanocatalyst Enables Targeted Treatment of APAP-Induced Liver Injury via Enhanced Macropinocytosis. [Abstract]2025 May 24:e2500507. PMID: 40411876 -
Acta Biomater
Hydrogel system with growth cone-targeted hydroxyapatite nanorods: Regulating calcium signals for peripheral nerve injury repair. [Abstract]2025 Jul 1:201:171-186. PMID: 40419070 -
Acta Biomater
A prodrug nanodevice co-delivering docetaxel and ROR1 siRNA for enhanced triple negative breast cancer therapy. [Abstract]2025 Jan 24:193:498-513. PMID: 39730101 -
Sci China Life Sci
Receptor affinity-selective differential dynamics of membrane fusion initiation govern deltacoronavirus cross-species transmission. [Abstract]2025 Oct 24. PMID: 41144156 -
Sci China Life Sci
Bactericidal ability of target acidic phospholipids and phagocytosis of CDC42 GTPase-mediated cytoskeletal rearrangement underlie functional conservation of CXCL12 in vertebrates. [Abstract]2024 Dec;67(12):2713-2729. PMID: 39279006 -
Sci China Life Sci
2022 Feb;65(2):341-361. PMID: 34047913 -
J Pharm Anal
Effect of cholesterol on distribution, cell uptake, and protein corona of lipid microspheres at sites of cardiovascular inflammatory injury. [Abstract]2025 Jul;15(7):101182. PMID: 40735031 -
Cell Commun Signal
Promoting AMPK/SR-A1-mediated clearance of HMGB1 attenuates chemotherapy-induced peripheral neuropathy. [Abstract]2023 May 4;21(1):99. PMID: 37143083 -
Cell Commun Signal
Clathrin- and dynamin-dependent endocytosis limits canonical NF-κB signaling triggered by lymphotoxin β receptor. [Abstract]2020 Nov 4;18(1):176. PMID: 33148272 -
Cell Commun Signal
A piggyBac-based TANGO GFP assay for high throughput screening of GPCR ligands in live cells. [Abstract]2019 May 23;17(1):49 PMID: 31122241 -
-
Int J Biol Macromol
2025 Apr 28;310(Pt 4):143599. PMID: 40306505 -
Int J Biol Macromol
Polyethylenimine-coated PLGA nanoparticles containing Angelica sinensis polysaccharide promote dendritic cells activation and associated molecular mechanisms. [Abstract]2022 May 15:207:559-569. PMID: 35288164 -
ACS Appl Mater Interfaces
Fullerol Initiates Stem Cell-Nanomaterials Interactions for Enhanced Tissue Regeneration via Clathrin-Mediated Endocytosis and Nuclear Factor Erythroid 2-Related Factor 2 Signaling. [Abstract]2025 Apr 17. PMID: 40241445 -
Drug Deliv
Ophthalmic formulation of methotrexate: a strategy of using the self-assembled LacAC4A nanoparticles for non-invasive drug delivery to the ocular posterior segment. [Abstract]2025 Dec;32(1):2509962. PMID: 40437914 -
-
Sci Total Environ
2021 Jul 20:779:146523. PMID: 34030247 -
Br J Pharmacol
A fibroblast-specific miRNA functional cluster in remote exosomes aggravates myocardial ischaemia/reperfusion injury via the Rap1b/ERK1/2 axis. [Abstract]2025 Nov 14. PMID: 41236828 -
Br J Pharmacol
2023 Jul;180(14):1878-1896. PMID: 36727262 -
Br J Pharmacol
An orally available hypoglycaemic peptide taken up by caveolae transcytosis displays improved hypoglycaemic effects and body weight control in db/db mice. [Abstract]2020 Aug;177(15):3473-3488. PMID: 32293707 -
Emerg Microbes Infect
Obatoclax inhibits SARS-CoV-2 entry by altered endosomal acidification and impaired cathepsin and furin activity in vitro. [Abstract]2022 Dec;11(1):483-497. PMID: 34989664 -
-
Microbiol Res
Staphylococcus aureus extracellular vesicles induce apoptosis and restrain mitophagy-mediated degradation of damaged mitochondria. [Abstract]2023 Aug:273:127421. PMID: 37267814 -
J Med Chem
Hsp70-Targeting Chimeras Enable Dual Proteasomal and Lysosomal Degradation of Intracellular and Extracellular Proteins. [Abstract]2026 Apr 9;69(7):8417-8432. PMID: 41874277 -
J Med Chem
AcGlcAs: A Novel P53-Targeting Arsenical with Potent Cellular Uptake and Cancer Cell Selectivity. [Abstract]2023 Dec 28;66(24):16579-16596. PMID: 38069817 -
Anal Chem
A Nongenetic Proximity-Induced FRET Strategy Based on DNA Tetrahedron for Visualizing the Receptor Dimerization. [Abstract]2020 Sep 1;92(17):11921-11926. PMID: 32689787 -
Int J Nanomedicine
2025 Dec 6:20:14613-14628. PMID: 41383278 -
Int J Nanomedicine
Engineered E. coli OMVs Carrying the Membrane-Binding hGC33 Fragment Precisely Target Liver Cancer and Effectively Treat Tumor. [Abstract]2025 May 22:20:6573-6590. PMID: 40433120 -
Int J Nanomedicine
Dual-Mode Treatment of Hepatocellular Carcinoma Using RGD Cyclopeptide-Modified Liposomes Loaded with Ce6/DOX. [Abstract]2025 Mar 27:20:3845-3860. PMID: 40165796 -
Phytother Res
Hordenine improves Parkinsonian-like motor deficits in mice and nematodes by activating dopamine D2 receptor-mediated signaling. [Abstract]2023 Aug;37(8):3296-3308. PMID: 36883794 -
Front Immunol
Mannose Receptor Mediates the Activation of Chitooligosaccharides on Blunt Snout Bream ( Megalobrama amblycephala) Macrophages. [Abstract]2021 Aug 2;12:686846. PMID: 34408745 -
Colloids Surf B Biointerfaces
A natural toolbox for brain delivery: Optimizing magnesium phosphate nanoparticles with "orifice-opening" compounds. [Abstract]2026 Jun:262:115536. PMID: 41678904 -
Colloids Surf B Biointerfaces
A dual-functional mitochondrial probe for melanoma visualization and PI3K/AKT/mTOR-EMT signaling axis-mediated antitumor therapy. [Abstract]2025 Jun 3:254:114847. PMID: 40482387 -
-
Pharmaceutics
Enhanced Ocular Bioavailability and Prolonged Duration via Hydrophilic Surface Nanocomposite Vesicles for Topical Drug Administration. [Abstract]2024 Nov 21;16(12):1496. PMID: 39771476 -
Drug Deliv Transl Res
Promoting oral absorption of Panax notoginseng saponins via thiolated trimethyl chitosan and wheat germ agglutinin-modified nanoformulation. [Abstract]2024 Mar;14(3):621-636. PMID: 37787882 -
-
Commun Biol
2022 Nov 14;5(1):1248. PMID: 36376440
Chlorpromazine purchased from MedChemExpress. Usage Cited in: Commun Biol. 2022 Nov 14;5(1):1248. [Abstract]
Chlorpromazine (CPZ) (10 µM; 30 min) remarkably decreases the cellular internalization of FITC-P-LPK in HCT116 cells. Chlorpromazine can inhibit clathrin-mediated endocytosis. The fluorescence intensity is observed by confocal microscopy and detected using a multi-well plate reader.
-
Int J Mol Sci
D-M159 Synergistically Induces Apoptosis in HeLa Cells Through Endoplasmic Reticulum Stress and Mitochondrial Dysfunction. [Abstract]2025 Mar 29;26(7):3172. PMID: 40243937 -
Pharm Biol
Kuhuang injection exerts a protective effect by activating PPAR-γ in an in vitro model of chlorpromazine-induced cholestatic liver injury constructed by tissue engineering. [Abstract]2022 Dec;60(1):1679-1689. PMID: 36063125 -
-
mBio
ATP1A1 enhances porcine reproductive and respiratory syndrome virus type 2 attachment and internalization. [Abstract]2026 Apr 8;17(4):e0389625. PMID: 41773865 -
mBio
2025 Mar 12;16(3):e0378724. PMID: 39964166 -
Biol Res
DYRK1-mediated phosphorylation of endocytic components is required for extracellular lumen expansion in ascidian notochord. [Abstract]2023 Mar 11;56(1):10. PMID: 36899423 -
Front Cell Dev Biol
Chlorpromazine affects autophagy in association with altered Rag GTPase-mTORC1-TFEB signaling. [Abstract]2023 Sep 8:11:1266198. PMID: 37745295 -
Front Cell Dev Biol
CD44v6-O-MWNTS-Loaded Gemcitabine and CXCR4 siRNA Improves the Anti-tumor Effectiveness of Ovarian Cancer. [Abstract]2021 Jul 7;9:687322. PMID: 34307366 -
Front Cell Dev Biol
Structural and Functional Characterization of Fibronectin in Extracellular Vesicles From Hepatocytes. [Abstract]2021 Mar 18:9:640667. PMID: 33816490 -
Comput Struct Biotechnol J
Dependence of SARS-CoV-2 infection on cholesterol-rich lipid raft and endosomal acidification. [Abstract]2021;19:1933-1943. PMID: 33850607 -
Toxins
Aflatoxin B1 and Aflatoxin M1 Induce Compromised Intestinal Integrity through Clathrin-Mediated Endocytosis. [Abstract]2021 Mar 2;13(3):184. PMID: 33801329 -
Antiviral Res
Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. [Abstract]2020 Jun;178:104786. PMID: 32251767 -
Langmuir
2020 Sep 29;36(38):11374-11382. PMID: 32902993 -
J Virol
The ASFV CD2v protein inhibits apoptosis by inducing proteasomal degradation of BimEL via activation of the TPL2-MEK-ERK signaling pathway. [Abstract]2026 Mar 24;100(3):e0195225. PMID: 41631827 -
J Virol
Porcine Deltacoronavirus Enters Porcine IPI-2I Intestinal Epithelial Cells via Macropinocytosis and Clathrin-Mediated Endocytosis Dependent on pH and Dynamin. [Abstract]2021 Nov 23;95(24):e0134521. PMID: 34586858 -
Microb Pathog
EIPA, A macropinocytosis blocking agent, inhibits Siniperca chuatsi rhabdovirus infection in vitro and in vivo. [Abstract]2025 May 26:206:107751. PMID: 40436219 -
Viruses
Bovine Parainfluenza Virus Type 3 (BPIV3) Enters HeLa Cells via Clathrin-Mediated Endocytosis in a Cholesterol- and Dynamin-Dependent Manner. [Abstract]2021 May 31;13(6):1035. PMID: 34072688 -
PLoS Negl Trop Dis
Identification of anti-flaviviral drugs with mosquitocidal and anti-Zika virus activity in Aedes aegypti. [Abstract]2019 Aug 20;13(8):e0007681. PMID: 31430351 -
J Leukoc Biol
Combination of microparticles vaccine with MSI-1436 exerts a strong immune response for hepatocellular carcinoma. [Abstract]2024 Jul 16:qiae159. PMID: 39012079 -
Insect Sci
Clathrin-dependent endocytosis predominantly mediates protein absorption by fat body from the hemolymph in Bombyx mori. [Abstract]2020 Aug;27(4):675-686. PMID: 30912872 -
Virus Res
Diphyllin elicits a doubled-pronged attack on the entry of SARS-CoV-2 by inhibiting cathepsin L and furin. [Abstract]2024 Oct 19:350:199485. PMID: 39424146 -
Virus Res
Muscovy duck reovirus enters susceptible cells via a caveolae-mediated endocytosis-like pathway. [Abstract]2020 Jan 15;276:197806. PMID: 31704247 -
Biochim Biophys Acta Gen Subj
An integrative method for evaluating the biological effects of nanoparticle-protein corona. [Abstract]2023 Mar;1867(3):130300. PMID: 36577488 -
-
-
-
-
-
-
-
-
-
-
Solvent & Solubility
DMSO : 100 mg/mL (313.62 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.84 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (7.84 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (283 KB)
-
SDS (480 KB)
- English - EN (480 KB)
- Français - FR (480 KB)
- Deutsch - DE (480 KB)
- Norwegian - NO (480 KB)
- Español - ES (480 KB)
- Swedish - SV (480 KB)
- Italian - IT (480 KB)
- Portuguese - PT (480 KB)
-
Handling Instructions (2659 KB)
References
[1]. Kamgar-Dayhoff P, et al. Multifaceted effect of chlorpromazine in cancer: implications for cancer treatment. Oncotarget. 2021 Jul 6;12(14):1406-1426. [Content Brief]
[2]. Shin SY, et al. The antipsychotic agent chlorpromazine induces autophagic cell death by inhibiting the Akt/mTOR pathway in human U-87MG glioma cells. Carcinogenesis. 2013 Sep;34(9):2080-9. [Content Brief]
[3]. Yang Z, et al. Cancer cell-intrinsic XBP1 drives immunosuppressive reprogramming of intratumoral myeloid cells by promoting cholesterol production. Cell Metab. 2022 Nov 2:S1550-4131(22)00461-2. [Content Brief]
[4]. Lee SJ, et al. Mechanism of inhibition by chlorpromazine of the human pain threshold sodium channel, Nav1.7. Neurosci Lett. 2017 Feb 3;639:1-7. [Content Brief]
[5]. Thomas D, et al. The antipsychotic drug chlorpromazine inhibits HERG potassium channels. Br J Pharmacol. 2003 Jun;139(3):567-74. [Content Brief]
[6]. Suzuki H, et al. Comparison of the anti-dopamine D₂ and anti-serotonin 5-HT(2A) activities of chlorpromazine, bromperidol, haloperidol and second-generation antipsychotics parent compounds and metabolites thereof. J Psychopharmacol. 2013 Apr;27(4):396-400. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.1362 mL | 15.6809 mL | 31.3617 mL | 78.4043 mL |
| 5 mM | 0.6272 mL | 3.1362 mL | 6.2723 mL | 15.6809 mL | |
| 10 mM | 0.3136 mL | 1.5681 mL | 3.1362 mL | 7.8404 mL | |
| 15 mM | 0.2091 mL | 1.0454 mL | 2.0908 mL | 5.2270 mL | |
| 20 mM | 0.1568 mL | 0.7840 mL | 1.5681 mL | 3.9202 mL | |
| 25 mM | 0.1254 mL | 0.6272 mL | 1.2545 mL | 3.1362 mL | |
| 30 mM | 0.1045 mL | 0.5227 mL | 1.0454 mL | 2.6135 mL | |
| 40 mM | 0.0784 mL | 0.3920 mL | 0.7840 mL | 1.9601 mL | |
| 50 mM | 0.0627 mL | 0.3136 mL | 0.6272 mL | 1.5681 mL | |
| 60 mM | 0.0523 mL | 0.2613 mL | 0.5227 mL | 1.3067 mL | |
| 80 mM | 0.0392 mL | 0.1960 mL | 0.3920 mL | 0.9801 mL | |
| 100 mM | 0.0314 mL | 0.1568 mL | 0.3136 mL | 0.7840 mL |